` GSK (GlaxoSmithKline PLC) vs FTSE All Share Index Comparison - Alpha Spread

GSK
vs
FTSE All Share Index

Over the past 12 months, GSK has outperformed FTSE All Share Index, delivering a return of -17% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
GSK vs FTSE All Share Index

Loading

Performance Gap
GSK vs FTSE All Share Index

Loading
GSK
FTSE All Share Index
Difference

Performance By Year
GSK vs FTSE All Share Index

Loading
GSK
FTSE All Share Index
Add Stock

Competitors Performance
GlaxoSmithKline PLC vs Peers

FTSE All Share Index
GSK
LLY
JNJ
NOVO B
ROG
Add Stock

GlaxoSmithKline PLC
Glance View

Economic Moat
None
Market Cap
56.5B GBX
Industry
Pharmaceuticals

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
1 626.61 GBX
Undervaluation 16%
Intrinsic Value
Price
Back to Top